Format

Send to

Choose Destination
See comment in PubMed Commons below
Blood Rev. 2013 Mar;27(2):63-70. doi: 10.1016/j.blre.2012.12.004. Epub 2013 Jan 20.

Lymphoid malignancies: Another face to the Janus kinases.

Author information

  • 1Diamantina Institute, University of Queensland, Brisbane, Australia. l.scott3@uq.edu.au

Abstract

Considerable attention has focused on the gain-of-function mutations in the Janus kinase-2 (JAK2) tyrosine kinase that are detectable in most patients with a myeloproliferative neoplasm. Activating mutations that target JAK2, as well as JAK1, or CRLF2 and IL7RA, two cytokine receptors with which the JAKs associate in lymphoid cells, have now been identified in a subset of pediatric patients diagnosed with acute lymphoblastic leukemia (ALL), many of whom have a poor prognosis. This review focuses on the biology of these acquired mutations, and discusses the therapeutic benefits for patients that are likely to arise as a consequence of their discovery.

Copyright © 2012 Elsevier Ltd. All rights reserved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk